Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05203172 · ClinicalTrials.gov registry record · Phase 4

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

A Phase 4 study of Solid Tumors, sponsored by Pfizer.

Recruiting
Registry status
Phase 4
Development phase
46
Enrollment target
20
Study locations

NCT05203172 is a Phase 4 study of Solid Tumors that is actively recruiting participants, run by Pfizer. The registered enrollment target is 46 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05203172, a Phase 4 study of Solid Tumors, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 4
Development phase
46 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they have not enrolled in a prior study of encorafenib or binimetinib. Participants that had enrolled but had stopped receiving the study treatment in a prior study cannot enrolled in this study. Participants in the FLOTILLA study will receive encorafenib and/or binimetinib at the same dose and frequency as in their prior study, for up to about 5 years.

Conditions Studied

Solid Tumors

Interventions

  • DRUG Binimetinib only treatment
  • DRUG Encorafenib only Treatment
  • DRUG Encorafenib & Binimetinib Treatment
  • DRUG Treatment of Encorafenib & Binimetinib & Ribociclib
  • DRUG Treatment of Encorafenib & Binimetinib & Cetuximab

Study Locations (20)

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Hospital - Atlanta
  • Investigational Drug Service Emory University Clinic - Atlanta
  • Winship Cancer Institute of Emory University - Atlanta

Missouri

  • Siteman Cancer Center - St Louis
  • Barnes-Jewish Hospital - St Louis
  • Washington University School of Medicine - St Louis
  • Washington University - St Louis

Minnesota

  • HealthPartners Cancer Research Center - Saint Paul
  • Regions Hospital Pharmacy - Saint Paul
  • HealthPartners Specialty Center - Saint Paul

Arizona

  • St. Joseph's Hospital and Medical Center - Phoenix
  • St. Joseph's Hospital and Medical Center - Phoenix

New York

  • Rockefeller Outpatient Pavilion (53rd Street) - New York
  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • Duke Cancer Center - Durham
  • Investigational Chemotherapy Service - Durham

Massachusetts

  • Massachusetts General Hospital - Boston

New Jersey

  • MSK Basking Ridge - Basking Ridge

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2022-07-05
Est. Completion 2029-07-31
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05203172

The ClinicalTrials.gov registry entry for NCT05203172 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Binimetinib only treatment is the first listed.

NCT05203172 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Georgia, Missouri, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05203172 about?

NCT05203172 is a clinical study titled "The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials". The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studi...

What is the current status of trial NCT05203172?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2022-07-05. Estimated completion is 2029-07-31.

What conditions does trial NCT05203172 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT05203172?

The interventions under investigation include: Binimetinib only treatment (DRUG), Encorafenib only Treatment (DRUG), Encorafenib & Binimetinib Treatment (DRUG), Treatment of Encorafenib & Binimetinib & Ribociclib (DRUG), Treatment of Encorafenib & Binimetinib & Cetuximab (DRUG).

Who is sponsoring clinical trial NCT05203172?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05203172 being conducted?

This trial has 20 study locations across Arizona, Georgia, Massachusetts, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.